-
公开(公告)号：WO2010053337A2
公开(公告)日：2010-05-14
申请号：PCT/KR2009/006590
申请日：2009-11-10
CPC classification number: A61K9/5047 , A61K9/5026 , A61K9/5042
Abstract: 본 발명은 약리학적 활성 성분을 포함하는 매트릭스; 및 상기 매트릭스 상에 서방성 막 형성 물질을 포함하는 서방성층을 포함하는 서방성 미립자에 관한 것이다. 본 발명의 서방성 미립자는 효과적인 약물의 이중 방출 제어가 가능할 뿐만 아니라, 적은 양의 코팅물질을 사용하는 경우에도 우수한 용출 특성을 나타낼 수 있다.
Abstract translation: 本发明涉及包含药理活性成分的基质; 以及在基质上含有缓释成膜物质的缓释层。 本发明的缓释微粒不仅能够有效地控制药物的双剂量，而且即使在使用少量涂料时也具有优异的洗脱特性。
-
公开(公告)号：WO2010062147A2
公开(公告)日：2010-06-03
申请号：PCT/KR2009/007068
申请日：2009-11-30
Abstract: 본 발명에 따른 아데포버 디피복실의 결정형은, 에틸알코올 용제화형인 것을 특징으로 한다. 이러한 아데포버 디피복실의 결정형의 제조방법은, 아데포버 디피복실을 무수 에틸알코올에 용해하는 공정, 및 용해 공정에 의해 얻어진 아데포버 디피복실 용액을 냉각 교반하여 결정을 형성시키는 공정을 포함한다. 본 발명에 따른 아데포버 디피복실의 결정형은, 용해도와 용해속도가 빠르고, 생체 안전성이 우수하며, 의약분야 등에서 폭넓은 활용이 가능하다.
Abstract translation: 根据本发明的阿德福韦酯的结晶形式是乙醇溶剂化形式。 制备阿德福韦酯结晶形式的方法包括以下步骤：将阿德福韦酯溶于无水乙醇中，冷却并搅拌通过溶解步骤获得的阿德福韦酯溶液形成晶体。 根据本发明的阿德福韦酯的结晶形式具有优异的溶解度和溶解速度，优异的生物安全性，可广泛应用于医疗领域。
-
公开(公告)号：WO2010005195A2
公开(公告)日：2010-01-14
申请号：PCT/KR2009/003472
申请日：2009-06-26
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: 아데포버 디피복실(adefovir dipivoxil)의 결정형 L의 제조방법으로서, 아데포버 디피복실의 이소프로필알코올 또는 아세트산에틸 용액에 항용매를 첨가하고 교반하여 결정을 생성시키는 방법에 개시되며, 이러한 제조방법에 따르면, 기존에 알려진 방법 보다 훨씬 온화한 조건에서 목적하는 아데포버 디피복실의 결정형 L을 균일하고 적절한 크기로 용이하게 얻을 수 있다.
Abstract translation:
喔仓库服务器的Diffie酸，一种生产（阿德福韦酯），O仓库构件到加法异丙醇或抗溶剂以迪菲酸的乙酸乙酯溶液并搅拌以产生一个判定的晶形l方法 根据该生产方法，希望的阿德福韦酯的结晶形式L可以在比先前已知的方法更温和的条件下以均匀和适当的尺寸容易地获得。
-
公开(公告)号：KR1020120021022A
公开(公告)日：2012-03-08
申请号：KR1020100085038
申请日：2010-08-31
Applicant: (주)아모레퍼시픽
IPC: C08K5/20 , C08L33/00 , C08J3/12 , A61K31/194
CPC classification number: C08K5/20 , A61K31/194 , C08J3/12 , C08L33/00
Abstract: PURPOSE: An aminoacid composition containing branched amino acid is provided to shield include a bitter taste or inherent smell of branched chain amino acid by including a polymer compound containing a carboxyl group. CONSTITUTION: An aminoacid composition comprises a branched aminoacid, and a polymer compound containing carboxy group. The branched amino acid comprises one or more selected from a group consisting of isoleucine, leucine and valine. The polymer compound containing a carboxy group comprises one or more selected from a group consisting anionic polymethacrylic acid copolymer, cellulose acetate phthalate, polyvinyl acetate phthalate and hydroxypropyl methylcellulose phthalate.
Abstract translation: 目的：提供含有支链氨基酸的氨基酸组合物，其包括含有羧基的高分子化合物，包括支链氨基酸的苦味或固有气味。 构成：氨基酸组合物包含支链氨基酸和含有羧基的高分子化合物。 支链氨基酸包含选自异亮氨酸，亮氨酸和缬氨酸的一种或多种。 含有羧基的高分子化合物包括选自阴离子聚甲基丙烯酸共聚物，乙酸邻苯二甲酸纤维素，聚乙酸乙烯邻苯二甲酸酯和羟丙基甲基纤维素邻苯二甲酸酯中的一种或多种。
-
公开(公告)号：KR1020100061401A
公开(公告)日：2010-06-07
申请号：KR1020090115960
申请日：2009-11-27
Applicant: (주)아모레퍼시픽
IPC: C07D487/04 , A61K47/10 , A61K47/26 , A61K9/00
CPC classification number: A61K9/08 , A61K9/20 , C07D487/04 , A61K9/0019 , A61K47/10 , A61K47/26
Abstract: PURPOSE: A crystalline form of adefovir dipivoxil, and a virus infection prevention and treatment pharmaceutical composition containing thereof are provided to secure the excellent living-body safety, solubility and dissolution velocity. CONSTITUTION: A crystalline form of adefovir dipivoxil is in a form of an ethyl alcohol solvent containing 0.3~0.7 equivalent of ethyl alcohol within the crystal lattice. The crystalline form of the adefovir dipivoxil has peaks of when measuring by the X-ray powder diffraction method at the 2 theta diffraction angle. The melting point of the crystalline form of the adefovir dipivoxil is 64~68 deg C and 76~80 deg C. A virus infection prevention and treatment pharmaceutical composition includes the crystalline form of the adefovir dipivoxil.
Abstract translation: 目的：提供阿德福韦酯的结晶形式和含有其的病毒感染预防和治疗药物组合物，以确保优异的活体安全性，溶解度和溶解速度。 构成：阿德福韦酯的结晶形式是在晶格内含有0.3〜0.7当量乙醇的乙醇溶剂形式。 当通过X射线粉末衍射法在2θ衍射角测量时，阿德福韦酯的结晶形式具有峰值。 阿德福韦酯的结晶形式的熔点为64〜68℃，76〜80℃。病毒感染预防和治疗药物组合物包括阿德福韦酯的结晶形式。
-
Patent Agency Ranking
公开(公告)号：KR101509489B1
公开(公告)日：2015-04-08
申请号：KR1020080111190
申请日：2008-11-10
Applicant: (주)아모레퍼시픽
Abstract: 본발명은발사르탄을함유하는고형경구제형의제조방법에관한것으로, 발사르탄을함유하는고형경구제형의제조방법은발사르탄및 약학적으로허용가능한첨가제를결합액과접촉시키는단계; 이로부터얻어진결과물을건조시키는단계; 이로부터얻어진건조물을과립화시키는단계; 및이로부터얻어진과립물에붕해제및 활택제를혼합하여압축시키는단계를포함한다. 본발명의제조방법에따르면붕해력및 용출율이우수한발사르탄함유경구제형을효과적으로제조할수 있다.
-
公开(公告)号：KR1020090101039A
公开(公告)日：2009-09-24
申请号：KR1020080065440
申请日：2008-07-07
Applicant: (주)아모레퍼시픽
IPC: C07D487/04
Abstract: PURPOSE: A method for manufacturing a crystalline L of adeforvir dipivoxil is provided to easily obtain the crystalline L of adeforvir dipivoxil of proper and same size. CONSTITUTION: A method for manufacturing a crystalline L of adeforvir dipivoxil comprises a step of adding anti-solvent in a solution. The solution is isopropyl alcohol or acetic acid ethyl. The solution is used two times as adefovir dipivoxil in weight to volume.
Abstract translation: 目的：提供一种用于制备耐阿维菌素的结晶L的方法，以容易地获得适当且相同尺寸的阿维拉片剂的结晶L。 构成：一种用于制造阿维拉片剂的结晶L的方法包括在溶液中加入抗溶剂的步骤。 溶液为异丙醇或乙酸乙酯。 该溶液以体重计重量使用阿德福韦酯两倍。
-
公开(公告)号：KR101729140B1
公开(公告)日：2017-04-26
申请号：KR1020100085038
申请日：2010-08-31
Applicant: (주)아모레퍼시픽
IPC: C08K5/20 , C08L33/00 , C08J3/12 , A61K31/194
Abstract: 본발명은분지쇄아미노산및 카르복실기를포함하는고분자화합물을포함하는조성물을개시한다. 상기조성물은아미노산의쓴 맛또는냄새가차폐되어복용하기편리하다. 또한본 발명은분지쇄아미노산과카르복실기를포함하는고분자화합물을혼합하는단계를포함하는분지쇄아미노산의쓴 맛또는냄새차폐방법을개시한다.
Abstract translation: 本发明公开了包含含有支链氨基酸和羧基的聚合物的组合物。 该组合物很容易摄入，因为它可以防止苦味或氨基酸的味道。 本发明还公开了支链氨基酸的苦味或气味遮蔽方法，其包括混合包含支链氨基酸和羧基的聚合物化合物的步骤。
-
公开(公告)号：KR1020110075011A
公开(公告)日：2011-07-05
申请号：KR1020117010529
申请日：2009-11-10
Applicant: (주)아모레퍼시픽
CPC classification number: A61K9/5047 , A61K9/5026 , A61K9/5042 , A61K9/16 , A61K47/50
Abstract: PURPOSE: A sustained release fine particle containing a matrix containing pharmaceutically active ingredients and a sustained release layer is provided to ensure excellent elution effect. CONSTITUTION: A sustained release fine particle comprises: a matrix containing pharmacologically active ingredients; and a sustained release layer containing a sustained release membrane forming material on the matrix. The sustained release membrane forming material is a water insoluble polymer, enteric polymer, soluble polymer, or mixture thereof. The insoluble polymer is ethyl cellulose, cellulose ether, acrylic acid ethyl-methacrylic acid methyl-methacrylic acid trimethyl ammonium ethyl chloride copolymer, polyvinyl acetate, and acrylic acid ethyl-methacrylic acid methyl copolymer or dispersion solution thereof. The soluble polymer is hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrolidone, or polyvinyl alcohol. The matrix further contains an excipient or binder.
Abstract translation: 目的：提供含有含有药物活性成分和持续释放层的基质的缓释微粒，以确保优异的洗脱效果。 构成：缓释微粒包括：含有药理活性成分的基质; 以及在基质上含有缓释膜形成材料的持续释放层。 缓释膜形成材料是水不溶性聚合物，肠溶聚合物，可溶性聚合物或其混合物。 不溶性聚合物是乙基纤维素，纤维素醚，丙烯酸乙基 - 甲基丙烯酸甲基 - 甲基丙烯酸三甲基铵乙基氯共聚物，聚乙酸乙烯酯和丙烯酸乙基 - 甲基丙烯酸甲基共聚物或其分散溶液。 可溶性聚合物是羟丙基纤维素，羟丙基甲基纤维素，聚乙烯吡咯烷酮或聚乙烯醇。 基质还含有赋形剂或粘合剂。
-
公开(公告)号：KR1020100052253A
公开(公告)日：2010-05-19
申请号：KR1020080111190
申请日：2008-11-10
Applicant: (주)아모레퍼시픽
CPC classification number: A61K31/41 , A61K9/0053 , A61K9/2095
Abstract: PURPOSE: A method for manufacturing a solid oral formulation containing valsartan is provided to effectively obtain an oral formulation having excellent disintegration force and dissolution rate. CONSTITUTION: A method for manufacturing a solid oral formulation containing valsartan comprises: a step of contacting valsartan and pharmaceutically acceptable additive with binding solution; a step of drying resultant; a step of granulating the dried resultant; and a step of mixing the granule with disintegrant and lubricant. The binding solution is water, or mixture of water and ethanol. The disintegrant is crospovidone.
Abstract translation: 目的：提供一种制备含缬沙坦固体口服制剂的方法，以有效获得具有优异的崩解力和溶出率的口服制剂。 构成：制备含缬沙坦的固体口服制剂的方法包括：将缬沙坦和药学上可接受的添加剂与结合溶液接触的步骤; 干燥结果的步骤; 造粒干燥物的步骤; 以及将颗粒与崩解剂和润滑剂混合的步骤。 结合溶液是水，或水和乙醇的混合物。 崩解剂是交聚维酮。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.019 seconds)
